{'fraction_non_alphanumeric': 0.034236804564907276, 'fraction_numerical': 0.0, 'mean_word_length': 6.163265306122449, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
High‐throughput sequencing of peripheral blood for minimal residual disease monitoring in childhood precursor B‐cell acute lymphoblastic leukemia: A prospective feasibility study

Minimal residual disease (MRD) measured on end‐of‐induction bone marrow (BM) is the most important biomarker for guiding therapy in pediatric acute lymphoblastic leukemia (ALL). Due to limited sensitivity of current approaches, peripheral blood (PB) is not a reliable source for identifying patients needing treatment changes. We sought to determine if high‐throughput sequencing (HTS) (next‐generation sequencing) of rearranged immunoglobulin and T‐cell receptor genes can overcome this and be used to measure MRD in PB.